Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF) (“Maple Leaf” or the “Company”) announces, further to its press release dated May 31, 2017, the following progress report from Cannabis Compliance Inc. (“CCI”):
“We have been contracted by Maple Leaf to assist in obtaining a license from Health Canada (the “License”) for their 80,000 square foot facility in Telkwa, British Columbia (the “B.C. Facility”) to produce and sell cannabis products under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). An abridged License application is being prepared by CCI, which will expand on Maple Leaf’s product portfolio to include not only dried cannabis, but also cannabis extracts and oil. The floor plan being developed for the B.C. Facility will optimize cultivation, incorporate required physical security design and risk management programs, and implement stringent QA/GMP programs to ensure full compliance with the ACMPR and production of high quality and safe cannabis products. The abridged License application is expected to be completed and submitted to Health Canada within two months. CCI will also be responsible to communicate with Health Canada during the License application process to address information requests during the licensing process. We have confidence that with Maple Leaf’s total commitment, we should be able to assist Maple Leaf to obtain the ACMPR license toward the end of 2017 as planned.” Reported by CCI.
CCI is Canada’s premium cannabis consulting firm for companies seeking to achieve licensing for cannabis. CCI has a variety of consultants who have extensive knowledge and experience in commercial cannabis operations in Canada for over a decade, advising on everything from genetics sourcing, cultivation, security and facility design, to quality assurance, regulatory licensing and business planning. CCI’s experts assist with obtaining Health Canada approval for programs and in ensuring compliance once the approval has been obtained. CCI, which focuses primarily in the cannabis space, is a sister company of NHP Consulting Inc. (“NHP”). NHP, which has been in business over 10 years on regulatory consulting for pharmaceutical, medical devices, food, cosmetic and health products, continues to focus in these areas.
For further information regarding Maple Leaf Green World Inc., please visit www.mlgreenworld.com.
About Maple Leaf Green World Inc.
Maple Leaf is a public Canadian company that focuses on the cannabis industry in North America with Company currently operates 3 cannabis projects: B.C. Canada, California and Nevada U.S.A. With over 10 years of extensive greenhouse management experience, it applies its eco-agriculture knowledge and cultivation technology to produce contaminant-free organic cannabis products. Maple Leaf’s long-term objective is to produce cannabis oil and export its products to approved countries.
This press release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable Canadian securities legislation. Specifically, this press release includes, but is not limited to, forward-looking statements with respect to the streamlining of Health Canada’s ACMPR license review process, anticipated approvals of the Company’s application for a license under the ACMPR, and construction of the B.C. Facility. Generally, forward-looking statements can be identified by the forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “projects”, “intends”, “anticipates”, or “does not anticipate”, or “believes”, or “variations of such words and phrases or state that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken”, “occur” or “be achieved”. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause the actual results, level of activity, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the development and operation of the Company’s projects, risks associated with general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments involving medical cannabis, inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favourable terms, the medical cannabis industry in Canada and the jurisdictions where the Company operates generally, income tax and regulatory matters, competition, crop failure, currency and interest rate fluctuations, regulatory approvals including approvals from the Health Canada of the Company’s ACMPR license application, and those factors discussed in the sections relating to risk factors of our business filed in the Company’s required securities filings on SEDAR. Although the Company has attempted to identify important factors that could cause results to differ materially from those contained in forward-looking statements, there may be other factors that cause results to be materially different from those anticipated, described, estimated, assessed or intended. There can be no assurance that any forward-looking statements will prove accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws. The statements in this press release are made as of the date of this press release. The Company undertakes no obligation to comment on analyses, expectations, or statements made by third parties in respect of the Company and CCI and the description of CCI in this press release was provided by CCI.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Maple Leaf Green World Inc. Raymond Lai
Chairman, President & CEO
Click here to connect with Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF) to receive an Investor Presentation.
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.